Brief: Biovica Gets Final Pricing Decision For Divitum TKa Test By Medicare
21/11/2023 09:25
Nov 21 (Reuters) - Biovica International AB
BIOVICb.ST :
* BIOVICA RECEIVES FINAL PRICING DECISION FOR DIVITUM TKA
TEST BY
MEDICARE EFFECTIVE 1ST JANUARY 2024
* CENTER FOR MEDICARE & MEDICAID SERVICES AGREED TO
CROSSWALK
DIVITUM TKA TO REIMBURSEMENT CODE 0058U
* DIVITUM TKA WILL BE PRICED AT USD 322 PER TEST EFFECTIVE
FROM
JANUARY 1ST, 2024
* DECISION MEANS HIGH PROBABILITY TO DELIVER IN LINE WITH,
OR EVEN
ABOVE, AVERAGE PRICE OF $400 PER TEST
Source text for Eikon: ID:nMFN6Qmm2L
Further company coverage: BIOVICb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))